Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy
Journal of Allergy and Clinical Immunology · 2024
DOI: 10.1016/j.jaci.2024.02.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024. Verfasst von Tarun Keswani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Mass. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Immunoglobulin G, Desensitization, Immunologic, Biomarkers. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Intramural NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Clinical efficacy of oral immunotherapy (OIT) has been associated with the induction of blocking antibodies, particularly those capable of disrupting IgE-allergen interactions. Previously, we identified mAbs to Ara h 2 and structurally characterized their epitopes. OBJECTIVE: We investigated longitudinal changes during OIT in antibody binding to conformational epitopes and correlated the results with isotype and clinical efficacy. METHODS: We developed an indirect inhibitory ELISA using mAbs to block conformational epitopes on immobilized Ara h 2 from binding to serum immunoglobulins from peanut-allergic patients undergoing OIT. We tested the functional blocking ability of mAbs using passive cutaneous anaphylaxis in mice with humanized FcεRI receptors. RESULTS: Diverse serum IgE recognition of Ara h 2 conformational epitopes are similar before and after OIT. Optimal inhibition of serum IgE occurs with the combination of 2 neutralizing mAbs (nAbs) recognizing epitopes 1.2 and 3, compared to 2 nonneutralizing mAbs (non-nAbs). After OIT, IgG4 nAbs, but not IgG1 or IgG2 nAbs, increased in sustained compared to transient outcomes. Induction of IgG4 nAbs occurs after OIT only in those with sustained efficacy. Murine passive cutaneous anaphylaxis after sensitization with pooled human sera is significantly inhibited by nAbs compared to non-nAbs. CONCLUSIONS: Serum IgE conformational epitope diversity remains unchanged during OIT. However, IgG4 nAbs capable of uniquely disrupting IgE-allergen interactions to prevent effector cell activation are selectively induced in OIT-treated individuals with sustained clinical efficacy. Therefore, the induction of neutralizing IgG4 antibodies to Ara h 2 are clinically relevant biomarkers of durable efficacy in OIT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Mass.
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Mass; Master de Biologie, École Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
- Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC.
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, Mass. Electronic address: sarita.patil@mgh.harvard.edu.
Förderung
- NIAID NIH HHS
- Intramural NIH HHS
- NCRR NIH HHS
- NIH HHS
- NCATS NIH HHS
Zitieren
APA
Keswani, T., LaHood, N. A., Marini-Rapoport, O., Karmakar, B., Andrieux, L., Reese, B., Sneed, S. L., Pedersen, L. C., Mueller, G. A., & Patil, S. U. (2024). Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2024.02.017
Vancouver
Keswani T, LaHood NA, Marini-Rapoport O, Karmakar B, Andrieux L, Reese B, et al. Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy. Journal of Allergy and Clinical Immunology. 2024. doi:10.1016/j.jaci.2024.02.017
BibTeX
@article{Keswani2024,
author = {Keswani, Tarun and LaHood, Nicole A and Marini-Rapoport, Orlee and Karmakar, Bijoya and Andrieux, Léna and Reese, Brian and Sneed, Sunny L and Pedersen, Lars C and Mueller, Geoffrey A and Patil, Sarita U},
title = {Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
doi = {10.1016/j.jaci.2024.02.017}
}
EUVIMED